This article is more than 5 years old. Information may no longer be current.
Positive results announced for cangrelor in patients undergoing PCI
Click Here to Manage Email Alerts
The Medicines Company has announced today the results of the pivotal phase 3 CHAMPION PHOENIX trial on its investigational antiplatelet agent cangrelor, stating that the drug has demonstrated a statistically significant improvement compared with clopidogrel among patients undergoing PCI.
This news follows just 4 months after the CHAMPION PHOENIX trial completed enrollment. Following successful data lock, data analysis indicated that the defined primary composite efficacy endpoint of death, MI, ischemia-driven revascularization and stent thrombosis was met. Specifically, cangrelor demonstrated statistically significant improvement as compared with clopidogrel, while safety outcomes were similar to those reported in prior trials, according to a press release issued by the manufacturer.
The trial results are planned to be presented at a major upcoming scientific meeting.
Deepak L. Bhatt
"We are looking forward to presenting detailed results to the medical community as soon as the data are fully analyzed," Deepak L. Bhatt, MD, MPH, chief of cardiology at VA Boston Healthcare System, co-principal investigator of the CHAMPION trials and chief medical editor of Cardiology Today Intervention, said in the release.